In last trading session, Integra Lifesciences Holdings Corp (NASDAQ:IART) saw 0.55 million shares changing hands with its beta currently measuring 1.29. Company’s recent per share price level of $16.81 trading at $0.11 or 0.66% at ring of the bell on the day assigns it a market valuation of $1.30B. That closing price of IART’s stock is at a discount of -94.29% from its 52-week high price of $32.66 and is indicating a premium of 14.04% from its 52-week low price of $14.45. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.73 million shares which gives us an average trading volume of 698.32K if we extend that period to 3-months.

For Integra Lifesciences Holdings Corp (IART), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.08. Splitting up the data highlights that, out of 5 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.43 in the current quarter.

Integra Lifesciences Holdings Corp (NASDAQ:IART) trade information

Upright in the green during last session for gaining 0.66%, in the last five days IART remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $16.81 price level, adding 2.61% to its value on the day. Integra Lifesciences Holdings Corp’s shares saw a change of -25.88% in year-to-date performance and have moved 6.19% in past 5-day. Integra Lifesciences Holdings Corp (NASDAQ:IART) showed a performance of -22.96% in past 30-days. Number of shares sold short was 3.31 million shares which calculate 4.42 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 49.06% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 86. It follows that stock’s current price would drop -18.98% in reaching the projected high whereas dropping to the targeted low would mean a loss of -18.98% for stock’s current value.

Integra Lifesciences Holdings Corp (IART) estimates and forecasts

This year revenue growth is estimated to rise 4.28% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 381.17M for the same. And 10 analysts are in estimates of company making revenue of 417.04M in the next quarter. Company posted 368.87M and 418.18M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around -3.83% while estimates for its earnings growth in next 5 years are of 5.92%.

Integra Lifesciences Holdings Corp (NASDAQ:IART)’s Major holders

Insiders are in possession of 14.28% of company’s total shares while institution are holding 93.31 percent of that, with stock having share float percentage of 108.86%. Investors also watch the number of corporate investors in a company very closely, which is 93.31% institutions for Integra Lifesciences Holdings Corp that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at IART for having 11.25 million shares of worth $327.92 million. And as of 2024-06-30, it was holding 14.5376 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 7.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.0412 of outstanding shares, having a total worth of $226.5 million.

On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.1 shares of worth $68.97 million or 5.31% of the total outstanding shares. The later fund manager was in possession of 3.43 shares on Dec 31, 2024 , making its stake of worth around $57.66 million in the company or a holder of 4.44% of company’s stock.